J Gen Virol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Gen Virol 87 (2006), 2577-2581; DOI 10.1099/vir.0.81932-0

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Voisset, C.
Right arrow Articles by Dubuisson, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Voisset, C.
Right arrow Articles by Dubuisson, J.
Agricola
Right arrow Articles by Voisset, C.
Right arrow Articles by Dubuisson, J.
© 2006 Society for General Microbiology

Short Communication

High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry

Cécile Voisset1, Anne Op de Beeck1,2, Pauline Horellou1, Marlène Dreux3, Thierry Gustot4, Gilles Duverlie1,5, François-Loic Cosset3, Ngoc Vu-Dac1 and Jean Dubuisson1

1 CNRS, Institut de Biologie de Lille (UMR8161), Institut Pasteur de Lille, 1 rue Calmette, BP447, 59021 Lille cedex, France
2 Free University of Brussels, Faculty of Medicine, Laboratory of Molecular Virology, Brussels, Belgium
3 INSERM-U412, ENS de Lyon, Lyon, France
4 Hôpital Erasme, Free University of Brussels, Brussels, Belgium
5 Laboratory of Virology, Centre Hospitalier Universitaire d'Amiens, Amiens, France

Correspondence
Ngoc Vu-Dac
ngoc.vu-dac{at}ibl.fr
Jean Dubuisson
jean.dubuisson{at}ibl.fr


   ABSTRACT
TOP
 ABSTRACT
MAIN TEXT
 REFERENCES
 
The neutralizing activity of anti-hepatitis C virus (HCV) antibodies is attenuated by a factor present in human sera, which has been proposed to be high-density lipoproteins (HDLs). HDLs have also been shown to facilitate the entry of HCV pseudoparticles (HCVpp) into target cells. Here, the aim of the study was to determine whether HDL-mediated facilitation of HCVpp and infectious HCV (HCVcc) entry and attenuation of neutralization are two related phenomena. The data indicated that HDLs attenuate neutralization at a constant rate. In addition, as for HDL-mediated facilitation of HCVpp entry, attenuation of neutralization depended on the expression of the scavenger receptor BI (SR-BI) and its selective lipid-uptake function. Finally, kinetic experiments showed that HDL-mediated facilitation of HCVpp entry is more rapid than virus neutralization. Altogether, these observations indicate that HCV is exploiting the physiological activity of SR-BI for promoting its entry into target cells, which consequently also protects the virus against neutralizing antibodies.


   MAIN TEXT
TOP
 ABSTRACT
 MAIN TEXT
REFERENCES
 
Detection of the presence of neutralizing antibodies in the sera of patients infected by Hepatitis C virus (HCV) has been hampered by the difficulties in establishing a robust and reliable cell-culture system for HCV propagation. Interestingly, the recent development of HCV pseudoparticles (HCVpp) (Bartosch et al., 2003bDown; Drummer et al., 2003Down; Hsu et al., 2003Down) has allowed confirmation of the presence of neutralizing antibodies in sera of chronically infected chimpanzees and humans (Bartosch et al., 2003aDown, bDown; Hsu et al., 2003Down; Lavillette et al., 2005bDown; Logvinoff et al., 2004Down; Meunier et al., 2005Down; Yu et al., 2004Down). However, it has been shown that the neutralization activity of antibodies from HCV-infected patients is attenuated by a factor present in human serum, which has been proposed to be high-density lipoproteins (HDLs) (Bartosch et al., 2005Down; Lavillette et al., 2005aDown; Meunier et al., 2005Down). At present, neither the intensity nor the mechanism of attenuation of neutralization by HDLs has been clearly determined. Interestingly, we and others have shown that HDLs are also able to facilitate HCVpp entry through a mechanism depending on the expression of the scavenger receptor BI (SR-BI) and its selective lipid-uptake function (Bartosch et al., 2005Down; Meunier et al., 2005Down; Voisset et al., 2005Down). Here, we sought to determine whether HDL-mediated facilitation of HCVpp entry and attenuation of neutralization are two related phenomena.

HCVpp containing subtype 1a envelope glycoproteins (strain H) and infectious JFH1 virus (HCVcc) were generated as described previously (Bartosch et al., 2003bDown; Rouillé et al., 2006Down; Wakita et al., 2005Down). Infection experiments were performed on Huh-7 cells (Nakabayashi et al., 1982Down). HCVpp and HCVcc were produced in lipoprotein-free medium (2 % fetal calf lipoprotein-depleted serum, LPDS) and neutralization experiments were also performed in medium supplemented with 2 % LPDS. Human HDL (density, 1.13–1.18 g ml–1) fractions from fresh human plasma were isolated as described by Hatch (1968)Down. A series of sera from patients infected chronically with various HCV genotypes was used.

To evaluate the impact of HDLs from HCV-positive sera on HCVpp neutralization, sera containing HDLs and antibodies were co-incubated with HCVpp and target cells. Classically, neutralization assays are performed by pre-incubating virus and sera from infected patients before contact with target cells. However, as HDLs potentially have an effect on virus entry by acting directly on the target cell, we considered that it would be more relevant to study the effect of HDLs on neutralization by co-incubating sera, HCVpp and target cells. In these conditions, we observed that only two of the 10 HCV-positive sera tested were able to neutralize HCVpp entry by >50 % (Fig. 1aDown). In contrast, all of the sera displayed a neutralizing activity in a classical neutralization assay based on a pre-incubation of HCVpp and serum before contact with target cells (Fig. 1aDown). These data show that, in most cases, HCV-positive sera are not able to neutralize HCVpp when antibodies and HDLs are incubated simultaneously with HCVpp and the cells.


Figure 1
View larger version (18K):
[in this window]
[in a new window]
  		Fig. 1. HDLs attenuate HCVpp neutralization at a constant rate. (a) Neutralization experiments were performed by either pre-incubating HCVpp with 2 % human sera from HCV-infected patients for 2 h at 37 °C before contact with Huh-7 cells (empty bars) or by simultaneous co-incubation of HCVpp, 2 % serum from HCV patients and Huh-7 cells for 3 h at 37 °C (shaded bars). HCV– corresponds to a representative healthy individual. Control experiments (ctrl) were performed by co-incubating HCVpp in medium supplemented with 2 % LPDS in the absence of human serum. (b) Neutralization experiments were performed by simultaneous co-incubation of HCVpp, antibodies purified from human sera (15 µg ml–1) and Huh-7 cells for 3 h at 37 °C in the absence (empty bars) or the presence (shaded bars) of 30 µg HDLs ml–1. (c) Neutralization experiments were performed by simultaneous co-incubation of HCVcc, antibodies purified from human sera (60 µg ml–1) and Huh-7 cells for 2 h at 37 °C in the absence or in the presence of 60 µg HDLs ml–1. Data obtained with patient P8 are representative of the data obtained by using antibodies from other patients that are able to neutralize HCVcc entry (data not shown). Infectivity was measured by quantification of the expression of E2 and is presented as percentage of infectivity of the untreated virus. (d) Each dot represents the ratio between the level of HCVpp infectivity obtained in the presence of both HDLs and antibodies, or in the presence of antibodies purified from the serum of HCV-infected patients. The results of (a) and (b) are presented as percentages of the infectivity relative to infectivity of HCVpp in 2 % LPDS medium (ctrl) in the absence of antibodies. Results are reported as the mean±SD of three independent experiments. Pseudoparticles bearing no envelope glycoproteins displayed an infectivity of <2 %.

 
As HCV-positive sera contain various concentrations of antibodies and HDLs, we used antibodies purified from HCV-positive sera and purified HDLs in our neutralization assay. The neutralizing activity of anti-HCV antibodies was analysed in the presence or absence of HDLs. As shown in Fig. 1(b, c)Up, the neutralizing activity of anti-HCV antibodies on HCVpp and HCVcc entry was reduced strongly in the presence of HDLs. Interestingly, the presence of HDLs always enhanced the infectivity levels of HCVpp by approximately three times (Fig. 1dUp). In addition, this enhancement of infectivity was very similar for all of the antibodies tested, whether they were neutralizing or not (Fig. 1dUp). Similar data were obtained by using HCVpp bearing E1E2 from different genotypes (data not shown). These data suggest that the constant enhancement obtained in the presence of HDLs may be related to a constitutive action of HDLs on target cells, independently of HCVpp neutralization by antibodies. This is in agreement with the absence of interaction between HDLs and HCVpp (Voisset et al., 2005Down).

To further investigate the mechanism of HDL-mediated attenuation of neutralization, we knocked down SR-BI expression. HDLs are indeed a physiological ligand of SR-BI (Rhainds & Brissette, 2004Down). RNA-interference experiments were done as described previously (Voisset et al., 2005Down). SR-BI-specific small interfering RNA (siRNA) downregulated SR-BI expression to approximately 70 % compared with the negative-control siRNA (data not shown). As observed previously (Voisset et al., 2005Down), when a specific siRNA against SR-BI was used, HCVpp infectivity was not affected in the absence of HDLs, whereas HDL-mediated enhancement of infectivity was reduced strongly (Fig. 2aDown). This contrasts with another study showing that silencing of SR-BI expression reduces HCVpp infectivity (Lavillette et al., 2005bDown). The discrepancy between these data may potentially be explained by differences in the levels of downregulation of expression of SR-BI in these experiments. Indeed, one cannot exclude the possibility that HCV requires only very small amounts of SR-BI to enter target cells. Interestingly, when SR-BI expression was downregulated, the efficiency of neutralization of sera was increased markedly and reached neutralization levels similar to those obtained with purified antibodies in the absence of HDLs (Fig. 2aDown). To further investigate the role of SR-BI in HDL-mediated attenuation of neutralization, we also analysed the effect of BLT-4, a drug known to block SR-BI-mediated selective uptake of HDL lipids (Nieland et al., 2002Down). This compound has also been shown to strongly reduce the HDL-mediated enhancement of HCVpp entry (Bartosch et al., 2005Down; Voisset et al., 2005Down). Interestingly, when the cells were treated by BLT-4, HCVpp were neutralized more efficiently by antibodies from HCV-positive patients, despite the presence of HDLs (Fig. 2bDown). These data indicate that HDL-mediated attenuation of HCVpp neutralization is dependent on SR-BI and its selective lipid-uptake property. In addition, they also show that HDL-mediated facilitation of HCVpp entry and attenuation of neutralization are two related phenomena.


Figure 2
View larger version (21K):
[in this window]
[in a new window]
  		Fig. 2. HDL reduction of HCVpp neutralization by HCV-positive sera depends on SR-BI and its selective lipid-uptake property. (a) SR-BI expression was downregulated as described previously (Lavillette et al., 2005bDown; Voisset et al., 2005Down). Neutralization experiments were performed by simultaneous co-incubation for 3 h at 37 °C of HCVpp, 2 % HCV+ serum and Huh-7 cells in which SR-BI expression was unmodified by thecontrol siRNA (empty bars) or Huh-7 cells in which SR-BI expression was downregulated by using a specific siRNA (shaded bars). *The results obtained are presented as percentages of the infectivity relative to infectivity of HCVpp in 2 % LPDS medium for control siRNA cells (ctrl, empty bar) in the absence of human serum. Under these conditions, HCVpp infectivity was 102 % in Huh-7 cells in which SR-BI expression was downregulated (ctrl, shaded bar). (b) The neutralization assay was performed by incubating simultaneously for 3 h at 37 °C HCVpp, 30 µg HDLs ml–1, 30 µg HCV+ antibodies ml–1 and Huh-7 cells in the absence (empty bars) or the presence (shaded bars) of 10 µM BLT-4 (ChemBridge; Nieland et al., 2002Down). Data obtained with patient P2 are representative of the data obtained by using antibodies from other patients (data not shown). The results are presented as percentages of the infectivity relative to infectivity of HCVpp in 2 % LPDS medium in the absence of antibodies (ctrl). Results are reported as the mean±SD of three independent experiments.

 
We then hypothesized that HDLs accelerate HCVpp entry and thus permit HCVpp to escape the immune response. Indeed, as we described previously, HDL facilitation of HCVpp entry is a post-binding event (Voisset et al., 2005Down), which indicates that HDLs may favour internalization of virions and thus escape from neutralization. Therefore, we analysed the kinetics of HCVpp entry in the presence of either HDLs or antibodies. It is important to note that the kinetic experiments were performed at early time points and, under these conditions, HCVpp infectivity had not yet reached saturation (data not shown). As shown in Fig. 3Down(a), HDL facilitation of HCVpp entry was already efficient after 15 min incubation, whereas neutralization by antibodies from HCV-infected patients was only observed after longer incubation times (Fig. 3aDown; data not shown). Thus, the kinetics of HDL facilitation of HCVpp entry were more rapid than the kinetics of neutralization by antibodies from HCV-infected patients. These data indicate that HDLs may overcome antibody neutralization by reducing the time window during which the antibodies can bind to and neutralize HCVpp.


Figure 3
View larger version (16K):
[in this window]
[in a new window]
  		Fig. 3. The kinetics of HDL facilitation are more rapid than the kinetics of neutralization of most anti-HCV antibodies. (a) Infections were performed in the presence of 30 µg HDLs ml–1 or antibodies purified from HCV-positive sera (30 µg ml–1). At several time points, the medium was removed, Huh-7 cells were washed once and incubated for 2 days before measuring the luciferase activities. Kinetics of HCVpp infectivity in the absence of HDLs and antibodies increased with time and did not reach saturation at 15, 30 or 45 min (data not shown). The kinetics shown were obtained by using antibodies purified from patient P10, and are representative of the kinetics obtained with the antibodies purified from the other patients (data not shown). The results are presented as percentages of infectivity relative to infectivity of HCVpp in 2 % LPDS medium for each time of the kinetics (ctrl). Neutralization experiments were performed in the absence (bullet) or the presence ({square}) of 30 µg HDLs ml–1 using increasing amounts of mAb H48 (b) (Bartosch et al., 2003Downb) and 9/27 (c) (Hsu et al., 2003Down). (d) Kinetics of HCVpp infection were performed in the presence of 30 µg HDLs ml–1 or 10 µg mAb H48 or 9/27 ml–1. At several time points, the medium was removed, Huh-7 cells were washed once and incubated for 2 days before measuring the luciferase activities. The results are presented as in (a) and are reported as the mean±SD of three independent experiments. Pseudoparticles bearing no envelope glycoproteins displayed an infectivity of <2%.

 
Antibodies purified from HCV-positive patients are a pool of antibodies potentially directed against various epitopes. In addition, the proportion of neutralizing antibodies in patient sera is unknown. We therefore also analysed the effect of HDLs on the behaviour of some well-characterized neutralizing mAbs. For the majority of neutralizing mAbs tested, the presence of HDLs attenuated their neutralizing activity, as shown for H48 (Fig. 3bUp). However, the neutralizing activity of mAb 9/27 was not affected by HDLs (Fig. 3cUp). Comparison of the kinetics of HCVpp entry in the presence of either HDLs or mAbs showed that, as observed for antibodies from HCV-infected patients, neutralization by mAb H48 was rather slow (Fig. 3dUp). In contrast to mAb H48, the kinetics of neutralization by mAb 9/27 were very rapid (Fig. 3dUp). Therefore, the absence of HDL effect on the neutralizing activity of mAb 9/27 is probably due to its rapid kinetics of neutralization, suggesting that mAb 9/27 might work slightly before HDLs can provide a signal to facilitate HCVpp entry. As neutralization by antibodies isolated from HCV-infected patients was attenuated by HDLs, neutralizing antibodies behaving like mAb 9/27 are probably induced poorly in a natural infection. Together, these data indicate that the rapid kinetics of HDL facilitation of HCVpp entry may allow HCVpp to escape partially from some neutralizing antibodies, like mAb H48, but not from all of them, as shown for mAb 9/27. The 9/27 epitope is located in HVR1 (Hsu et al., 2003Down), whereas the H48 epitope is conformation-dependent (J. Dubuisson, unpublished data) and is located in the CD81-binding region of E2 (J. Ball & A. Patel, personnal communication). Our data indicate that the difference of neutralization between 9/27 and H48 in the presence of HDLs is probably related to their relative affinity for their respective epitope and/or to the accessibility of these epitopes. However, we cannot exclude the possibility that mAbs 9/27 and H48 recognize different epitopes, which may be required for interactions with receptor(s) that are influenced differentially by HDLs.

The exact role of SR-BI in HCV entry is far from understood. SR-BI has been shown to modulate the plasma-membrane composition (Huang et al., 2003Down; Peng et al., 2004Down). The relationship between SR-BI and HCV infection may thus be based on the capacity of SR-BI to modulate the lipid composition of the plasma membrane to render the membrane permissive to HCV entry. In agreement with this hypothesis, the SR-BI-mediated selective uptake of lipids from HDLs has been shown to enhance HCVpp entry markedly (Bartosch et al., 2005Down; Voisset et al., 2005Down). It is thus tempting to speculate that SR-BI is involved at some stage of HCV entry by modulating the plasma-membrane composition.

In conclusion, our data demonstrate that HDLs reduce HCVpp neutralization by accelerating HCVpp entry, through the lipid-transfer property of SR-BI. The rapid kinetics of HDL facilitation of HCVpp entry may allow HCVpp to escape some neutralizing antibodies. While antibodies bind to HCVpp and neutralize their entry, HDLs accelerate the entry of HCVpp that are not yet neutralized.


   ACKNOWLEDGEMENTS
 
We thank Czeslaw Wychowski and David Delgrange for their help with the HCVcc system. We also thank Angéline Bilheu, Sophana Ung and André Pillez for excellent technical assistance and Birke Bartosch and Laurence Cocquerel for critical reading of the manuscript. We also thank J. McKeating and T. Wakita for the gift of reagents. This work was supported by grants from the Agence Nationale de Recherche sur le Sida et les hépatites virales (ANRS), INSERM (ATC ‘hépatite C’) and the Association pour la Recherche sur le Cancer (ARC). C. V. was supported by an ANRS post-doctoral fellowship. J. D. is an international scholar of the Howard Hughes Medical Institute.


   REFERENCES
TOP
 ABSTRACT
 MAIN TEXT
 REFERENCES
 
Bartosch, B., Bukh, J., Meunier, J.-C., Granier, C., Engle, R. E., Blackwelder, W. C., Emerson, S. U., Cosset, F.-L. & Purcell, R. H. (2003a). In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 100, 14199–14204.[Abstract/Free Full Text]

Bartosch, B., Dubuisson, J. & Cosset, F.-L. (2003b). Infectious hepatitis C virus pseudo-particles containing functional E1–E2 envelope protein complexes. J Exp Med 197, 633–642.[Abstract/Free Full Text]

Bartosch, B., Verney, G., Dreux, M., Donot, P., Morice, Y., Penin, F., Pawlotsky, J.-M., Lavillette, D. & Cosset, F.-L. (2005). An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 79, 8217–8229.[Abstract/Free Full Text]

Drummer, H. E., Maerz, A. & Poumbourios, P. (2003). Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett 546, 385–390.[CrossRef][Medline]

Hatch, F. T. (1968). Practical methods for plasma lipoprotein analysis. Adv Lipid Res 6, 1–68.[Medline]

Hsu, M., Zhang, J., Flint, M., Logvinoff, C., Cheng-Mayer, C., Rice, C. M. & McKeating, J. A. (2003). Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100, 7271–7276.[Abstract/Free Full Text]

Huang, Z. H., Gu, D., Lange, Y. & Mazzone, T. (2003). Expression of scavenger receptor BI facilitates sterol movement between the plasma membrane and the endoplasmic reticulum in macrophages. Biochemistry 42, 3949–3955.[CrossRef][Medline]

Lavillette, D., Morice, Y., Germanidis, G. & 8 other authors (2005a). Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 79, 6023–6034.[Abstract/Free Full Text]

Lavillette, D., Tarr, A. W., Voisset, C. & 7 other authors (2005b). Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41, 265–274.[CrossRef][Medline]

Logvinoff, C., Major, M. E., Oldach, D. & 7 other authors (2004). Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 101, 10149–10154.[Abstract/Free Full Text]

Meunier, J.-C., Engle, R. E., Faulk, K. & 7 other authors (2005). Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A 102, 4560–4565.[Abstract/Free Full Text]

Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T. & Sato, J. (1982). Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42, 3858–3863.[Abstract/Free Full Text]

Nieland, T. J. F., Penman, M., Dori, L., Krieger, M. & Kirchhausen, T. (2002). Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc Natl Acad Sci U S A 99, 15422–15427.[Abstract/Free Full Text]

Peng, Y., Akmentin, W., Connelly, M. A., Lund-Katz, S., Phillips, M. C. & Williams, D. L. (2004). Scavenger receptor BI (SR-BI) clustered on microvillar extensions suggests that this plasma membrane domain is a way station for cholesterol trafficking between cells and high-density lipoprotein. Mol Biol Cell 15, 384–396.[Abstract/Free Full Text]

Rhainds, D. & Brissette, L. (2004). The role of scavenger receptor class B type I (SR-BI) in lipid trafficking: defining the rules for lipid traders. Int J Biochem Cell Biol 36, 39–77.[CrossRef][Medline]

Rouillé, Y., Helle, F., Delgrange, D. & 10 other authors (2006). Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol 80, 2832–2841.[Abstract/Free Full Text]

Voisset, C., Callens, N., Blanchard, E., Op De Beeck, A., Dubuisson, J. & Vu-Dac, N. (2005). High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 280, 7793–7799.[Abstract/Free Full Text]

Wakita, T., Pietschmann, T., Kato, T. & 9 other authors (2005). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11, 791–796.[CrossRef][Medline]

Yu, M. Y. W., Bartosch, B., Zhang, P. & 7 other authors (2004). Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A 101, 7705–7710.[Abstract/Free Full Text]

Received 9 February 2006; accepted 24 April 2006.


This article has been cited by other articles:


Home page
 GutHome page
J M Timpe and J A McKeating
Hepatitis C virus entry: possible targets for therapy
Gut, December 1, 2008; 57(12): 1728 - 1737.
[Full Text] [PDF]

Home page
 J. Virol.Home page
L. Meertens, C. Bertaux, L. Cukierman, E. Cormier, D. Lavillette, F.-L. Cosset, and T. Dragic
The Tight Junction Proteins Claudin-1, -6, and -9 Are Entry Cofactors for Hepatitis C Virus
J. Virol., April 1, 2008; 82(7): 3555 - 3560.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. von Hahn and C. M. Rice
Hepatitis C Virus Entry
J. Biol. Chem., February 15, 2008; 283(7): 3689 - 3693.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Dreux, B. Boson, S. Ricard-Blum, J. Molle, D. Lavillette, B. Bartosch, E.-I. Pecheur, and F.-L. Cosset
The Exchangeable Apolipoprotein ApoC-I Promotes Membrane Fusion of Hepatitis C Virus
J. Biol. Chem., November 2, 2007; 282(44): 32357 - 32369.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. X. Johansson, C. Voisset, A. W. Tarr, M. Aung, J. K. Ball, J. Dubuisson, and M. A. A. Persson
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus
PNAS, October 9, 2007; 104(41): 16269 - 16274.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. T. Catanese, R. Graziani, T. von Hahn, M. Moreau, T. Huby, G. Paonessa, C. Santini, A. Luzzago, C. M. Rice, R. Cortese, et al.
High-Avidity Monoclonal Antibodies against the Human Scavenger Class B Type I Receptor Efficiently Block Hepatitis C Virus Infection in the Presence of High-Density Lipoprotein
J. Virol., August 1, 2007; 81(15): 8063 - 8071.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
F. Helle, A. Goffard, V. Morel, G. Duverlie, J. McKeating, Z.-Y. Keck, S. Foung, F. Penin, J. Dubuisson, and C. Voisset
The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein
J. Virol., August 1, 2007; 81(15): 8101 - 8111.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. Grove, T. Huby, Z. Stamataki, T. Vanwolleghem, P. Meuleman, M. Farquhar, A. Schwarz, M. Moreau, J. S. Owen, G. Leroux-Roels, et al.
Scavenger Receptor BI and BII Expression Levels Modulate Hepatitis C Virus Infectivity
J. Virol., April 1, 2007; 81(7): 3162 - 3169.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. B. Kapadia, H. Barth, T. Baumert, J. A. McKeating, and F. V. Chisari
Initiation of Hepatitis C Virus Infection Is Dependent on Cholesterol and Cooperativity between CD81 and Scavenger Receptor B Type I
J. Virol., January 1, 2007; 81(1): 374 - 383.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Voisset, C.
Right arrow Articles by Dubuisson, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Voisset, C.
Right arrow Articles by Dubuisson, J.
Agricola
Right arrow Articles by Voisset, C.
Right arrow Articles by Dubuisson, J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS